Background-Rare variant accumulation studies can implicate genes in disease susceptibility when a significant burden is observed in patients versus control subjects. Such analyses might be particularly useful for candidate genes that are selected based on experiments other than genome-wide association studies (GWAS). We sought to determine whether rare variants in non-GWAS candidate genes identified from mouse models and human mendelian syndromes of hypertriglyceridemia (HTG) accumulate in patients with polygenic adult-onset HTG. Methods and Results-We resequenced protein coding regions of 3 genes with established roles (APOC2, GPIHBP1, LMF1) and 2 genes recently implicated (CREB3L3 and ZHX3) in TG metabolism. We identified 41 distinct heterozygous rare variants, including 29 singleton variants, in the combined sample; in total, we observed 47 rare variants in 413 HTG patients versus 16 in 324 control subjects (odds ratioϭ2.3; Pϭ0.0050). Post hoc assessment of genetic burden in individual genes using 3 different tests suggested that the genetic burden was most prominent in the established genes LMF1 and APOC2, and also in the recently identified CREB3L3 gene. Conclusions-These extensive resequencing studies show a significant accumulation of rare genetic variants in non-GWAS candidate genes among patients with polygenic HTG, and indicate the importance of testing specific hypotheses in large-scale resequencing studies. (Circ Cardiovasc Genet. 2012;5:66-72.)
H igh-throughput resequencing can detect rare variant accumulation in case-control studies of complex disease. 1 However, hypothesis-driven approaches are required to focus analyses on subsets of genes with increased a priori probability of harboring rare variation associated with increased susceptibility to a complex disease phenotype. One hypothesis is that genomic loci containing common small effect variants-such as lipid-associated loci identified by the Global Lipid Genetics Consortium 2 (GLGC) genome-wide association study (GWAS)-will harbor genes in which rare variants are also associated with disease susceptibility. We recently confirmed this hypothesis in patients with hypertriglyceridemia (HTG)-a complex trait defined by plasma triglyceride (TG) concentration Ͼ95th percentile-by showing a significant excess of rare variants in candidate genes selected from GWAS (APOA5, GCKR, LPL, and APOB) in HTG patients compared with normolipidemic control subjects. 3 However, common variation associated with plasma lipid concentrations from GWAS only explains Ϸ25% of the estimated genetic component, 2 suggesting a potential contribution from as yet unidentified genes.
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Currently, the source of "missing heritability" in complex traits is a topic of intense speculation. 4 The contribution of rare variation and higher-order gene-gene and gene-environment interactions may contribute to such unexplained variation. Alternatively, common variation associated with plasma lipids by GWAS may only represent a fraction of loci in which genetic variation is responsible for trait modulation. For the sake of brevity and clarity, we hereafter refer to candidate genes in genomic loci containing common variation associated with a metabolic trait or disease phenotype by GWAS as "GWAS-identified genes," whereas we define "non-GWAS-identified genes" as candidate genes selected based on criteria other than GWAS association signals. For instance, common variants with negligible effect sizes in genes that are essential in modulation of a metabolic trait could elude detection by epidemiologically sized GWAS (eg, false-negative associations), perhaps as the result of overly stringent significance thresholds. Also, important disease-associated genes may not necessarily harbor common variants and thus could not be detected by the GWAS approach. 5 However, non-GWAS genes associated with a metabolic trait may still harbor rare genetic variants that contribute to disease susceptibility. For instance, several non-GWAS genes have been implicated in TG metabolism by pregenome-era biochemical studies of patients with mendelian HTG syndromes, 6 and naturally-occurring or genetically-engineered mutants causing HTG in mice. Extensive resequencing of such genes and evaluation of rare variant accumulation could help identify additional genetic variation responsible for increasing susceptibility to human HTG.
We assessed the burden of rare variants in non-GWAS HTG-associated candidate genes in adults with severe HTG. We resequenced five non-GWAS candidate genes that were either implicated in mouse HTG models or in human mendelian HTG syndromes, including the known genes APOC2, 7 GPIHBP1, 8 and LMF1, 9 and the recently identified genes CREB3L3 10 and ZHX3. 11 We evaluated the genetic burden of rare nonsynonymous variants across these 5 genes in 413 unrelated adult polygenic HTG patients and 324 normolipidemic population-based control subjects. We defined rare variants using a frequency Ͻ1% in the combined cohort. Furthermore, we evaluated in parallel the potential role of three statistical tests, proposed for detection of variant excess in rare variant resequencing studies. Our study demonstrates a genetic burden of rare variants is present in individual non-GWAS candidate genes in patients with polygenic adult-onset HTG compared with healthy population-based control subjects.
Methods

Study Subjects
This study was approved by the University of Western Ontario Institutional Review Board (protocol No. 07920E) and ethics boards at collaborating institutions. All subjects provided informed consent for collection of clinical data, and DNA extraction and analysis. In total, 413 adult HTG patients and 324 population-based control subjects were included in this study. HTG patients were unrelated subjects of European ancestry with plasma TG concentration Ͼ95th percentile (3.37 mmol/L) ascertained from a single tertiary referral lipid clinic in London, Canada. Population-based control subjects were European subjects ascertained through the Study of Health Assessment and Risk in Ethnic Groups, 12 as previously described. Control subjects with fasting plasma TG concentration Ͼ2.3 mmol/L were excluded from analyses due to potentially undiagnosed HTG but were otherwise not phenotypically selected, thus limiting the possibility of finding potentially protective variants that might be expected in supernormal control subjects. Biochemical analyses of lipoprotein traits were conducted separately in each cohort, as previously described. 12, 13 HTG patients and healthy control subjects were matched for European ancestry, using whole genome genotyping data available from Johansen et al. 3 Identify-by-state and multidimensional scaling analyses were used to confirm the European ancestry of study samples relative to HapMap control subjects (online-only Data Supplement Figure I ); study subjects with X-axis values ϾϪ0.01 were removed before analysis. Subjects without whole genotyping data (75 HTG patients and 12 healthy control subjects) were retained in our analysis; however removal of these subjects before a sensitivity analysis confirmed that there was no material difference in our results or interpretation (data not shown). Baseline clinical data are shown in Table 1 .
Candidate Gene Selection
HTG-associated candidate genes were selected for sequencing based on mouse models and mendelian syndromes of HTG. We hypothesized that homozygous mutations causing early-onset (pediatric) HTG in humans may also contribute to adult-onset HTG in the heterozygous form. All genes were implicated in TG metabolism through direct or indirect effects on lipoprotein lipase (LPL) activity or expression. APOC2 was selected based on knowledge that homozygous mutations cause severe early-onset (pediatric) monogenic HTG in humans. 7, 13 GPIHBP1 and LMF1 were each selected because knockout mouse models had HTG and rare homozygous loss-of-function mutations caused severe early-onset HTG. 8, 9 Creb3l3, encoding the transcription factor Creb-h, was hypothesized to be an important regulator of nutrient and energy metabolism in mice. 10 Recent studies demonstrated that Creb-h was involved in regulation of phosphoenolpyruvate carboxykinase 2 and glucose-6-phosphatase in vivo and that Creb3l3 expression is modulated by fasting and insulin-resistant states. 14 Elucidation of the in vivo function of Creb3l3 led to the creation of a knockout mouse strain, which had a fasting HTG phenotype. The human ortholog CREB3L3 was thus suspected as a candidate gene for HTG susceptibility. 10 Finally, Zhx3 was initially identified as a candidate gene for lipid metabolism; it is a member of a family of 3 transcription factors, of which Zhx2 was previously shown to regulate both TG and cholesterol levels. 11 Linkage analysis of HDL cholesterol concentration and gene expression patterns in liver and adipose identified candidate HDL-associated loci in the progeny of a cross between two inbred mouse strains with distinct HDL profiles, namely CAST/EiJ and C57BL/6J (online-only Data Supplement Figure II) . Zhx3 was directly under the linkage peak and exhibited a strong expression QTL that correlated particularly with HDL levels. None of the selected candidate genes were associated with HTG by GWAS in the recent study by Johansen et al 3 (online-only Data Supplement Figure  IIIA through IIIE). These 5 genes were selected completely a priori; no additional genes were selected for the experiments reported here. The GWAS-identified genes APOA5, GCKR, LPL, and APOB had been previously sequenced in this cohort. 3 Lipid measurements were conducted after a 12-hour fasting period. Values are meanϮSD. LDL-C is not accurately calculated using the Friedewald equation for HTG patients when plasma TG concentration exceeds 4.5 mmol/L.
Genomic DNA Sequencing
All subjects were bidirectionally sequenced across exons and intronexon boundaries of APOC2, CREB3L3, GPIHBP1, LMF1, and ZHX3, using an ABI 3730 Automated DNA Sequencer (Applied Biosystems, Foster City, CA). Subjects missing sequencing data in any gene were removed from the study before analysis. All variants were called using automated software (Applied Biosystems, Foster City, CA), manually curated, and confirmed by repeat analysis. Rare variants were defined by frequency Ͻ1% in the combined cohort of HTG patients and control subjects to minimize rare variant selection bias. 15, 16 Thus, uncommon variants were defined by frequency Ͻ5% in the combined cohort, whereas common variants were defined by combined frequency Ͼ5%. Rare variants were annotated based on identification of public databases using dbSNP 132 and 1000 Genomes Project May 2011 data releases. Predictions of deleterious effect were made using established software, including Polyphen-2 17 (Polymorphism Phenotyping v2) and SIFT 18 (Sorting Intolerant from Tolerant). We refer to nonsynonymous variants as sequence variations causing amino acid substitutions (missense variants) or introduction of a premature protein truncation (nonsense variants). Intronic variants were excluded from our analysis because only Ϸ50-bp of intronic DNA that flanked target exons had been sequenced, although no variants were identified that affect intron-exon boundaries.
Statistical Analysis
Summary statistics are displayed as meanϮSD. Rare variant accumulation was assessed across all genes (Tables 2 and 3) , using Fisher exact test in SAS v9.2 (Cary, NC). Nominal statistical significance was defined as a 2-sided PϽ0.05. Where indicated, rare variant carriers were defined as having Ն1 rare variant. Filtration of variants based on predictions of deleterious effect in silico was based on 0 predictions, 1 prediction from either SIFT (as damaging) or Polyphen-2 (as possibly or probably damaging), or 2 predictions from both SIFT and Polyphen-2. Nonsense mutations were ranked as analogous to having 2 predictions of deleterious effect, as they cannot be processed with either algorithm.
Rare variant accumulation was assessed in individual genes (Table 4) , using 3 post hoc analyses of genetic burden (general case-control comparison, C-␣, and the variable threshold approach) as implemented in PlinkSeq (http://atgu.mgh.harvard.edu/plinkseq). The general burden test was chosen as method that was parallel to Fisher exact test and could compare minor alleles in HTG patients and healthy control subjects using a permutation-based approach. The C-␣ test statistic was chosen because it is suggested to be capable of measuring genetic burden across a locus in the setting of variants with a mixture of protective and deleterious directions of effect. 19 The variable threshold analysis was chosen as an analysis strategy that increases the weight of very rare variants, such as those likely to be functionally significant. 20 Empirical probability values were calculated in parallel for all statistical tests using 10 000 permutations.
Results
Resequencing of HTG-associated candidate genes in 413 HTG patients and 324 healthy control subjects identified 47 distinct missense or nonsense variants in HTG patients and healthy control subjects (online-only Data Supplement Table I ), including 41 heterozygous rare variants (minor allele frequency [MAF] Ͻ1%), 3 heterozygous uncommon variants (MAF 1% to 5%), and 3 common variants (MAF Ͼ5%). Only 3 of 41 (7.3%) rare variants were annotated in public databases such as dbSNP (v132) or 1000 Genomes Project (May 2011 release), whereas all common and uncommon variants had been previously identified.
Rare nonsynonymous variants were most abundant in genes established in HTG pathophysiology: APOC2 harbored the largest number of rare variants relative to its size, followed by LMF1, ZHX3, CREB3L3, and GPIHBP1, which harbored 19.8, 11.2, 8.0, and 7.9 and 7.2 variants/kb, respectively. Among these HTG indicates hypertriglyceridemia; Co, control subjects; OR, odds ratio; CI, confidence interval. The in silico filter refers to the number of algorithms (0, 1, or 2) predicting deleterious functional effects of variants included in rare variant accumulation analysis. Polyphen-2 (possibly and probably damaging) or SIFT (damaging) were used to make predictions. Truncation mutations were given a score of 2. This analysis included 413 HTG patients and 324 population-based control subjects.
variants, 6 were identified in both HTG patients and control subjects, 28 were identified exclusively in HTG patients, and 7 exclusively in control subjects (Figure) . The vast majority of rare variants were singletons (29/41), as opposed to doubletons (6/41), tripletons (2/41), or variants with other frequencies (4/41) (online-only Data Supplement Table I ).
Rare nonsynonymous variants were found to be in large excess among HTG patients (Table 2 ). In total, we found 47 rare variants in 413 HTG patients and 16 rare variants in 324 control subjects, corresponding to a 2.3-fold increase in variants found in HTG patients (Pϭ0.0050). Only 5 HTG patients and 1 healthy control subject were carriers of 2 rare variants, which had virtually no effect on the observed accumulation (odds ratio [OR]ϭ2.2, Pϭ0.012). These associations were maintained when uncommon variants with MAF Ͻ5% were included in the analysis (Table 2) . At a 5% allele frequency threshold, we found 86 variants in HTG patients and 41 variants in healthy control subjects, corresponding to a 1.7-fold increase in variants found in HTG patients (Pϭ0.015). We identified 15 HTG patients and 6 healthy control subjects carrying 2 uncommon or rare variants, which again had a minimal effect on the observed accumulation (ORϭ1.6; Pϭ0.036). Interestingly, rare synonymous variants were over-represented in healthy control subjects at the Ͻ1% frequency threshold (ORϭ0.62; Pϭ0.035), but not at the Ͻ5% frequency threshold (ORϭ0.75; Pϭ0.13) (online-only Data Supplement Table II ). However, the apparent accumulation of synonymous variants appears to be driven by a single synonymous variant, LMF1 A287A, which is individually associated with control status (Pϭ0.21; ORϭ0.013). Removal of this variant from accumulation analysis abrogated the cumulative association at the Ͻ1% frequency threshold (ORϭ0.73; Pϭ0.20). 
Figure.
Rare variants identified by resequencing hypertriglyceridemia (HTG)-associated candidate genes in HTG patients and healthy control subjects. Variants above gene maps were identified in 413 HTG patients; variants below gene maps were identified in 324 healthy control subjects. Rare variants are colored based on identification in both cases and control subjects (black), identification in only cases or control subjects (blue), or proven biological dysfunction or truncation (red). Variant nomenclature refers to functional protein sequences without signal peptides. Rare variants were identified by bidirectional capillary-based sequencing of protein coding regions, defining rare variants as having a combined sample frequency Ͻ1%.
We next hypothesized that enrichment for rare nonsynonymous variants with increased likelihood of full penetrance would similarly accumulate in HTG patients. Accordingly, we assessed rare variant accumulation in HTG patients and healthy control subjects using predictions of deleterious effect from SIFT and Polyphen-2. An excess of rare variants in HTG patients was maintained when nonsynonymous variants were filtered by either 1 or 2 predictions of deleterious effects in silico (Table 3 ). There were 31 of 41 different rare variants predicted by Ն1 algorithm to have a deleterious effect in silico, including a total of 33 variants in 413 HTG patients compared with 9 variants in 324 control subjects, which corresponded to a 2.9-fold increase in variants found in HTG patients (Pϭ0.0037). Furthermore, 17 of 41 rare variants were predicted by both algorithms to have deleterious effects in silico, including 16 variants in HTG patients and 3 variants in healthy control subjects, corresponding to a 4.2-fold increase in variants found in HTG patients (Pϭ0.017). The accumulation of rare variants with predictions of deleterious effect was consistent at the Ͻ5% frequency threshold (Table 3 ). There were 34 of 41 rare variants predicted by Ն1 algorithm to have deleterious effect in silico, including 72 variants in HTG patients and 34 variants in healthy control subjects, corresponding to a 1.7-fold increase in HTG susceptibility (Pϭ0.021). The subset of variants with 2 predictions of deleterious effect in silico was identical under both 1% and 5% frequency thresholds.
An advantage of a multilocus association analysis is increased statistical power to detect a burden of rare variants in cases versus control subjects. However, an inherent limitation is the inability to implicate specific genes in disease pathophysiology. To assess the individual burden of rare variant accumulation in specific genes among HTG patients and control subjects, we used 3 different post hoc analyses (Table 4 ). These were (1) a general test of burden; (2) a variance-based analysis using the C-␣ test statistic 19 ; and (3) a recently proposed variable-threshold analysis, 20 all of which require permutation-based analyses to obtain empirical probability values for variant accumulation. A significant accumulation of rare variants was confirmed empirically across all loci by the general burden test (Pϭ0.0015) and the variable threshold approach (Pϭ0.0042), but no differences were observed using the C-␣ test statistic (Pϭ0.30). Virtually identical results were observed for a frequency threshold of Ͻ5%, as a significant accumulation was detected using the general burden test (Pϭ0.0066) and the variable threshold approach (Pϭ0.0010), but not with the C-␣ test statistic (Pϭ0.15). Among individual genes, rare variant accumulation was detected in CREB3L3 and APOC2 using the general burden test (Pϭ0.0081 and Pϭ0.013, respectively) and the variable threshold approach (Pϭ0.0081 and Pϭ0.015, respectively). A significant accumulation of variants was detected in LMF1 using the variable threshold approach (Pϭ0.035), but not with the general test of burden (Pϭ0.071). These analyses did not detect significant rare variant accumulation in either GPIHBP1 (Pϭ0.58 -0.73) or ZHX3 (Pϭ0.20 -0.33). The C-␣ test statistic could not detect significant rare variant accumulation in any particular gene.
Discussion
The principal finding of this study is that a significant excess of rare variants was identified by extensive resequencing of non-GWAS candidate genes selected based on mouse models and monogenic syndromes of HTG in patients with adultonset HTG. In total, 41 heterozygous missense and nonsense rare variants were identified across GPIHBP1, LMF1, CREB3L3, APOC2, and ZHX3 in 413 HTG patients and 324 control subjects, corresponding to a significant 2.3-fold increase of variants in HTG patients. Variants with increased likelihood of mechanistic effect based on in silico predictions accumulated similarly in HTG patients versus control subjects. Furthermore, post hoc analyses of genetic burden assessed among individual genes suggested that rare variant accumulation was greater in LMF1, APOC2, and CREB3L3, than in GPIHBP1 or ZHX3. Together, these analyses suggest that rare variation in HTG-associated candidate genes is strongly associated with polygenic HTG susceptibility.
Our study provides a proof-of-principle that rare variant accumulation analyses can help implicate individual genes in complex phenotypes without prior identification by GWAS. Multilocus association tests that group rare variants from many genes together provide increased power to detect an association with disease phenotypes; however, they are unable to identify the contribution of specific genes to the overall association. We first conducted a multilocus association to evaluate our main hypothesis that non-GWAS candidate genes would harbor an excess of rare variants in HTG patients. We next conducted post hoc gene-centric analyses using three different methods to empirically implicate specific genes in HTG susceptibility. These latter analyses were of particular interest for the two recently identified genes CREB3L3 and ZHX3 in particular. Both the general test of burden and the variable threshold approach were generally similar in their identification of rare variant accumulation in LMF1, CREB3L3, and APOC2 as associated with HTG susceptibility, whereas C-␣ did not identify such a burden for any specific gene.
The differences in performance between statistical analyses are probably related to their respective designs and also to the distribution of variants in our sample. For instance, the variable threshold approach provides increased weight to very rare variants, which in retrospect was a favorable weighting scheme for our study, since 70% of rare variants identified in our study were singletons. In contrast, C-␣ seems designed to detect genetic burden when genes have numerous rare variants with opposing directions of effect. However, C-␣ appears inadequately adapted to analyze numerous singleton variants in cases versus control subjects, and did not detect a genetic burden of rare variants in any genes or among all genes. Since recurrent rare variants seem to be optimal for this analysis, the large number of singleton variants in our sample could provide a reason for the difference in performance between the 3 post hoc analyses.
Our study supports the contribution of rare variants in LMF1, CREB3L3, and APOC2 to HTG pathophysiology. Most notably, we found that CREB3L3 is significantly involved in both TG metabolism and HTG susceptibility. CREB3L3 was recently implicated in TG metabolism as a transcription factor that regulates expression of cofactors required for TG-rich lipoprotein metabolism including APOC2, APOA5, and APOA4 10 ; some rare variants in this gene identified by our study have been shown to abrogate protein function 10 but has never been identified in a pure mendelian form of HTG. In contrast, APOC2 and LMF1 are established genes in TG metabolism: APOC2 encodes an essential lipoprotein lipase (LPL) cofactor required for hydrolysis of TG-rich lipoproteins, 21 whereas LMF1 encodes a maturation factor required for lipoprotein lipase activity. 9 Importantly, our findings cannot exclude the potential contribution of genetic variation in GPIHBP1 or ZHX3 to HTG susceptibility, since these genes have been implicated in lipoprotein pathophysiology through other means. For instance, GPIHBP1 encodes a cell-surface scaffold required for transendothelial LPL transport, 8 which is absolutely necessary for TG-rich lipoprotein metabolism. Functionally characterized heterozygous mutations in GPIHBP1 [22] [23] [24] have been reported in patients with HTG; however, only the G56R mutation that lacks any obvious functional deficit 25, 26 was identified in our study. It is probable that we were unable to show a significant accumulation of rare variants in GPIHBP1, due to small gene size, and relatively low power to detect increased genetic burden on an individual gene basis. Conversely, given the abundance of rare variants in ZHX3 found in both HTG patients and healthy control subjects, statistical power probably was not an issue in this gene and any association with the HTG phenotype would be tenuous at best. ZHX3 encodes a protein homologous to ZHX2, a developmental regulator of lipid metabolism, 11 although perhaps rare variants in this gene do not contribute to polygenic HTG susceptibility.
It is possible that some variants identified in HTG patients and healthy control subjects have arisen due to ancestry. However, we believe it is highly unlikely that population stratification is an artifact underlying the accumulation of rare variants in our study because (1) our sample was matched based on European ancestry using high-density genotyping data; and (2) sensitivity analyses removing subjects with unconfirmed data did not alter our results or interpretation. Furthermore, rare variant accumulation after filtration based on predictions of deleterious effect in silico was consistently observed in HTG patients. This analysis would have reduced the contribution of any single gene to the overall rare variant tally ensuring a more stringent and uniform signal arising from genes selected under our initial hypothesis.
Although the low frequency of HTG-associated rare variants will not likely account of the majority of unattributed variation in HTG diagnoses, many rare variants identified by our study likely contribute to polygenic HTG pathophysiology. Interestingly, the effect size of nonsynonymous variants with 2 predictions of deleterious effect (ORϭ4.2) begin to approximate the impact of carrying one common apo A-V S19W dysfunctional variant (ORϭ5.35), 13 which is the best single genetic marker so far reported for polygenic HTG. 6 Future cosegregation analyses of rare variants within families complemented by functional in vitro analyses will establish specific variants that directly increase HTG risk.
In summary, our results indicate the importance of framing hypotheses and selecting analytic strategies that apply not only for Sanger resequencing projects, but also for future exome and targeted resequencing studies, particularly in the absence of prior GWAS association signals for complex phenotypes. Specifically, resequencing 5 genes implicated in mouse models and mendelian syndromes of HTG has helped to identify an accumulation of rare nonsynonymous variants in polygenic HTG patients compared with normolipidemic population-based control subjects. These findings support a cumulative burden of rare variants in both known and novel genes in human polygenic HTG and underscore the importance testing predefined hypotheses in whole-exome and genome resequencing studies of complex traits.
